NYSE:XON -
The current stock price of XON is 4.65 null. In the past month the price decreased by -21.32%. In the past year, price decreased by -39.61%.
Intrexon Corporation is a biotechnology company. It provides synthetic biology services. The Company designs and produces modular DNA control systems and applications for human therapeutics, protein production, industrial products, agricultural biotechnology, and animal sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery. Intrexon Corporation is based in Germantown, Maryland.
INTREXON CORP
20374 Seneca Meadows Parkway
Germantown MD 20876
CEO: Randal J. Kirk
Phone: 301-556-9900
The current stock price of XON is 4.65 null. The price decreased by -4.12% in the last trading session.
The exchange symbol of INTREXON CORP is XON and it is listed on the New York Stock Exchange, Inc. exchange.
XON stock is listed on the New York Stock Exchange, Inc. exchange.
INTREXON CORP (XON) has a market capitalization of 756.48M null. This makes XON a Small Cap stock.
INTREXON CORP (XON) has a resistance level at 5.83. Check the full technical report for a detailed analysis of XON support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
XON does not pay a dividend.
INTREXON CORP (XON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.94).
ChartMill assigns a fundamental rating of 2 / 10 to XON. XON may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months XON reported a non-GAAP Earnings per Share(EPS) of -0.94. The EPS decreased by -30.56% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -393.13% | ||
ROA | -81.6% | ||
ROE | N/A | ||
Debt/Equity | 0.97 |